Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelofibrosis

Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

Bone Marrow Transplantation volume 33, pages 1005–1009 (2004)Cite this article

Summary:

The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n=5), chronic myelomonocytic leukemia (CMML) (n=8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n=7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%–67%), and disease-free survival 37% (95% CI 17–58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classication of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting – Airlie house, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.

    Article  CAS  Google Scholar 

  2. Montefusco E, Alimena G, Coco L et al. Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 1992; 65: 17–21.

    Article  CAS  Google Scholar 

  3. Kantarjian HM, Kurzrock R, Talpaz M . Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol/Oncol Clin N Am 1990; 4: 389–404.

    Article  CAS  Google Scholar 

  4. Hessling J, Kroger, Werner M et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769–772.

    Article  Google Scholar 

  5. Przepiorka D, Giralt S, Khouri I et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24–28.

    Article  CAS  Google Scholar 

  6. Anderson JE, Sale G, Appelbaum FR et al. Allogeneic marrow transplantation for primary myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010–1016.

    Article  CAS  Google Scholar 

  7. Singhal S, Powles R, Treleaven J et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16: 743–746.

    CAS  Google Scholar 

  8. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220–226.

    Article  CAS  Google Scholar 

  9. O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822–1826.

    Article  CAS  Google Scholar 

  10. Guardiola P, Esperou H, Cazals-Hatem D et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997; 98: 1004–1009.

    Article  CAS  Google Scholar 

  11. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  Google Scholar 

  12. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  13. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  14. Prentice RL, Kalbfleisch JD . The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554.

    Article  CAS  Google Scholar 

  15. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  Google Scholar 

  16. Reilly JT . Pathogenesis and management of idiopathic myelofibrosis. Bailliere's Clin Haematol 1998; 11: 751–767.

    Article  CAS  Google Scholar 

  17. Rajantie J, Sale GE, Deeg HJ et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986; 67: 1693–1697.

    CAS  Google Scholar 

  18. Creemers GJ, Lowenberg B, Hagenbeek A . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82: 772–773.

    Article  CAS  Google Scholar 

  19. Soll E, Massumoto C, Clift RA et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667–4673.

    CAS  Google Scholar 

  20. Onida F, Kantarjian HM, Smith TL et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.

    Article  CAS  Google Scholar 

  21. Fenaux P, Beuscart R, Lai JL et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1998; 6: 1417–1424.

    Article  Google Scholar 

  22. Tefferi A, Hoagland HC, Therneau TM, Pierre RV . Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64: 1246–1254.

    Article  CAS  Google Scholar 

  23. Wattel E, Guerci A, Hecquet B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480–2487.

    CAS  PubMed  Google Scholar 

  24. Beran M, Kantarjian H, O’Brien S et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473–2479.

    CAS  PubMed  Google Scholar 

  25. Zang DY, Deeg HJ, Gooley T et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110: 217–222.

    Article  CAS  Google Scholar 

  26. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

    Article  CAS  Google Scholar 

  27. Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Progr) 2001; 375–391.

    Article  Google Scholar 

  28. Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.

    Article  CAS  Google Scholar 

  29. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplant, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    P Mittal, R M Saliba, S A Giralt, M Shahjahan, A I Cohen, S Karandish, R E Champlin & M de Lima

  2. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    F Onida & M Beran

Authors
  1. P Mittal
    View author publications

    Search author on:PubMed Google Scholar

  2. R M Saliba
    View author publications

    Search author on:PubMed Google Scholar

  3. S A Giralt
    View author publications

    Search author on:PubMed Google Scholar

  4. M Shahjahan
    View author publications

    Search author on:PubMed Google Scholar

  5. A I Cohen
    View author publications

    Search author on:PubMed Google Scholar

  6. S Karandish
    View author publications

    Search author on:PubMed Google Scholar

  7. F Onida
    View author publications

    Search author on:PubMed Google Scholar

  8. M Beran
    View author publications

    Search author on:PubMed Google Scholar

  9. R E Champlin
    View author publications

    Search author on:PubMed Google Scholar

  10. M de Lima
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to M de Lima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mittal, P., Saliba, R., Giralt, S. et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 33, 1005–1009 (2004). https://doi.org/10.1038/sj.bmt.1704472

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704472

Keywords

This article is cited by

Search

Advanced search

Quick links